Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

International Adhesions Society Renews Call for Pain Treatment Alternatives and Welcomes CDC Warnings about Alarming Prescription Drug Deaths in U.S. Women
  • USA - English


News provided by

International Adhesions Society

Jul 11, 2013, 03:00 ET

Share this article

Share toX

Share this article

Share toX

International Adhesions Society (IAS)
International Adhesions Society (IAS)

Healthcare providers should offer a variety of pain treatment options, including and emphasizing those that do not involve prescription drugs

Post this

Dallas, TX (PRWEB) July 11, 2013 -- According to recent statistics published by the U.S. Centers for Disease Control (CDC), 18 women die daily from prescription painkiller overdoses, more than ever before. While over 10,000 men died of overdoses in 2010, deaths among women (6,600) increased five-fold (400%) in the previous decade, compared with an increase of 265% in men. These deaths are the tip of the iceberg. For every woman who dies, 30 go to the emergency room for painkiller misuse or abuse. According to the CDC, the opioid problem affects women in different ways than men. Women are more likely to have chronic pain, are prescribed narcotics at higher doses and for longer periods.

This report comes as no surprise to the International Adhesions Society (IAS), whose predominantly female members suffer from debilitating pain and complications related to internal scars resulting from surgery, trauma or inflammatory conditions, such as endometriosis, or related conditions such as irritable bowel syndrome (IBS) or interstitial cystitis (IC). Indeed, the IAS recently submitted its own research to help address gender inequality in women’s need for and access to pain relief.

The IAS research was derived from a survey of opioid use in over 2800 chronic pain patients, including 2399 (92%) women, and supported by nine other patient advocacy groups. Over 85% of these patients had used opioids for more than 3 months, and over 70% for more than one year. Side effects were moderate in 27% of patients and severe and intolerable in 21%. Even though side effects can occur at any dose, 24% of patients were taking what are considered high doses of opioids, more than the equivalent of 100mg of morphine daily.

States Dr. Wiseman, Founder of the IAS, “Pain management in America is based on the flawed notion that drugs are the best method for pain relief, and that opioids are the drugs of choice.” Dr. Wiseman continues, “It is time we wean ourselves from opioids by funding, developing and facilitating access to pharmaceutical and non-pharmaceutical alternatives to opioids. We welcome and endorse CDC’s recommendation that health care providers discuss pain treatment options that do not involve prescription drugs.“

Accordingly, the IAS renews its call for expedited FDA and reimbursement approval for newly developed alternatives to opioids as well as expanded reimbursement for existing alternatives such as physical and psycho-therapy. Opioid abuse, misuse, addiction and side effects cost society over $56 billion per year, providing a financial as well as medical incentive to pursue alternatives to opioids.

The IAS also contends that simply imposing stricter limits on opioid prescription labeling, currently being considered by FDA, would curtail access to opioids for millions of chronic pain patients who have few alternatives. According to the aforementioned IAS survey, these proposed limits would render opioid use “off-label” in over 92% of chronic pain patients and reduce access to, or reimbursement for opioids in over 80% of them. “We agree with the CDC that health care providers should responsibly prescribe prescription painkillers by monitoring patients for substance abuse and mental health problems and discussing the risks and benefits of taking painkillers for chronic conditions. But with these precautions, access to prescription pain medications by legitimate pain patients must continue until alternative pain relief methods are more widely available and reimbursed by insurance companies,” states Dr. Wiseman.

One such alternative is a therapeutic ultrasound device, PainShield® MD, which was evaluated in a clinical trial by the International Adhesions Society in patients with chronic pelvic, bladder, genital and musculoskeletal pain. The reduction in pain, as well as the lower need for opioids in some patients was considered so beneficial that a company, KevMed LLC, was established to make the device widely available to patients in the United States.

About the International Adhesions Society
The International Adhesions Society (IAS) provides awareness, information, advocacy, support and research for patients and their families suffering from adhesions - internal scars that connect organs or tissues that are not normally connected, as well as Adhesion Related Disorder (ARD) and Complex Abdomino-Pelvic Pain Syndrome (CAPPS). The IAS was founded and is funded by Synechion, Inc., a company providing R&D consulting services focusing on adhesions and related conditions.

David Wiseman, PhD, International Adhesions Society, http://www.adhesions.org, 972-931-5596, [email protected]

Modal title

International Adhesions Society Public Comments to IPRCC
View PDF
International Adhesions Society Public Comments to IPRCC
IAS Statement to FDA on Opioid Label Proposals
View PDF
IAS Statement to FDA on Opioid Label Proposals
International Adhesions Society Public Comments to IPRCC IAS Statement to FDA on Opioid Label Proposals

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.